Pharmafile Logo

News and Press Releases

Kainova Therapeutics Expands Phase I/II Trial of DT-7012, a Treg-depleting Anti-CCR8 Antibody, with First Patient Dosed in Europe

First patient dosed in France, expanding the DOMISOL study beyond Australia DT 7012 is being evaluated as monotherapy and in combination with pembrolizumab in a global clinical development program. 9...

Category: Biotechnology, Clinical Trials, Drug Discovery, Other, Pharmaceutical
Posted: April 9, 2026

Kainova Therapeutics
contact@kainovatx.com
7171 Frederick Banting Montreal, QC H4S 1Z9 Canada

Kainova Therapeutics Announces Positive Phase I Results for DT-9081, an Oral EP4 Receptor Antagonist, in Advanced Solid Tumors

Phase I results demonstrate favorable safety, sustained target engagement, and early signs of anti-tumor activity Reinforce EP4 receptor antagonism as a validated, high-value strategy to overcome immunotherapy resistance. 10 March...

Category: Biotechnology, Clinical Trials, Drug Discovery, Other, Pharmaceutical
Posted: March 10, 2026

Kainova Therapeutics
contact@kainovatx.com
7171 Frederick Banting Montreal, QC H4S 1Z9 Canada

Lytix Biopharma Publishes Comprehensive Review on the Transformative Potential of Oncolytic Peptides in Leading Cancer Journal (JITC)

17 February 2026 -- Oslo, Norway -- Lytix Biopharma AS, a clinical-stage immuno-oncology company, today announced the publication of a review article in the Journal of ImmunoTherapy of Cancer (JITC)....

Category: Biotechnology, Drug Discovery, Other, Pharmaceutical
Posted: February 17, 2026

Lytix Biopharma
post@lytixbiopharma.com
Sandakerveien 138, 0484 Oslo, Norway

Kainova Therapeutics Secures $32M CAD to Accelerate Development of Immuno-Oncology and Inflammation Therapies

Financing led by Investissement Québec with continued support from long-standing investors Plans include the acceleration of clinical development of breakthrough GPCR targeting treatments for patients. 10 February 2026 -- Montreal,...

Category: Drug Discovery, Other, Pharmaceutical
Posted: February 10, 2026

Kainova Therapeutics
contact@kainovatx.com
7171 Frederick Banting Montreal, QC H4S 1Z9 Canada

New Research Team for Multispecific Biologics in Collaboration with Daiichi Sankyo Starts at the BioMed X Institute in Heidelberg

The new research team will work on multispecific biologics to target innovative pathways in the tumor microenvironment (TME) 23 October 2025 -- Heidelburg, Germany -- BioMed X, a leading innovation hub for...

Category: Biotechnology, Drug Discovery, Other, Pharmaceutical
Posted: October 23, 2025

BioMed X
info@bio.mx
BioMed X GmbH Im Neuenheimer Feld 515 69120 Heidelberg

Lundbeck and Contera Pharma announce research collaboration to advance RNA-targeting medicines for serious neurological conditions

20 October 2025 -- Valby, Denmark -- H. Lundbeck A/S and Contera Pharma today announced a strategic research collaboration aiming to accelerate the discovery and development of innovative oligonucleotide-based medicines...

Category: Biotechnology, Drug Discovery, Logistics, Other, Pharmaceutical
Posted: October 20, 2025

Lundbeck
Iveco House Station Road Watford Hertfordshire WD17 1ET

Nabla Bio Signs Second Takeda Collaboration to Advance AI-Driven Design of Protein Therapeutics

Nabla to receive upfront and research cost payments in double-digit millions and eligible to receive success-based payments that may exceed $1 billion Multi-year partnership deploys Nabla Bio’s AI design and...

Category: Biotechnology, Clinical Trials, Drug Discovery, Other, Pharmaceutical
Posted: October 14, 2025

Nabla Bio
bd@nabla.bio
Riverside Technology Center
 840 Memorial Dr
 Cambridge, MA 02139

IAVI, Minapharm, and ProBioGen Announce Memorandum of Understanding to Progress Clinical Development, Manufacturing, Commercialization, and Access to Vaccines and Antibodies in Africa

Partners will advance end-to-end development of biologics for regionally prioritized diseases starting with Mpox and HIV 10 October 2025 -- Cairo, Egypt; Berlin, Germany; and New York, New York -- IAVI,...

Category: Biotechnology, Drug Delivery, Logistics, Manufacturing and Packing, Other, Pharmaceutical
Posted: October 10, 2025

ProBioGen
info@probiogen.de
Herbert-Bayer-Straße 8 13086 Berlin

Rezon Bio launches as a European biologics CDMO combining cost efficiency and digital innovation.

New brand with proven track record – EMA and FDA-audited mirrored-capability sites in Poland provide an accelerated path from development to commercialization 29 September 2025 -- Gdańsk, Poland -- Rezon...

Category: BioManufacturing, Logistics, Manufacturing and Packing, Other, Pharmaceutical
Posted: September 29, 2025

Rezon Bio
office@rezonbio.com
Trzy Lipy 3, Building A 80-172 Gdansk, Poland

Domain Therapeutics to Present Data on its GPCR Lead Programs at AACR Annual Meeting 2025

Presentation of Phase I clinical results from DT-9081, an EP4 receptor antagonist, and preclinical data on DT-7012, a Treg depleting anti-CCR8 antibody Preclinical findings highlight immuno-oncology breakthrough properties for its...

Category: Biotechnology, Clinical Trials, Drug Discovery, Other, Pharmaceutical
Posted: April 1, 2025

Domain Therapeutics
contact@domaintherapeutics.com
PARC D'INNOVATION 220 Boulevard Gonthier D'Andernach 67400 Strasbourg - Illkirch - France

H&T Presspart Launches Vytal®: Innovative snap-fit closure solution for advanced therapeutics

25 March 2025 – Marsberg, Germany – H&T Presspart (a division of the Heitkamp & Thumann Group), a leading developer and manufacturer of drug delivery components and devices for the...

Category: Drug Delivery, Manufacturing and Packing
Posted: March 25, 2025

H&T Presspart
blackburn@presspart.com
Presspart Manufacturing Ltd. Whitebirk Industrial Estate Blackburn, Lancashire BB1 5RF, England

BioMed X Institute and Merck Successfully Complete Extrachromosomal DNA in Cancer Research Project

The research of BioMed X team EDC - Extrachromosomal DNA in Cancer - has uncovered critical insights into the mechanisms driving extrachromosomal DNA (ecDNA) formation and maintenance, offering potential avenues for...

Category: Clinical Trials, Drug Discovery, Other, Pharmaceutical
Posted: February 6, 2025

BioMed X
info@bio.mx
BioMed X GmbH Im Neuenheimer Feld 515 69120 Heidelberg

Orion and Invenra announce discovery service and commercial license agreement to develop innovative bispecific antibody cancer therapeutics

30 January 2025 -- Espoo, Finland -- Orion Corporation and Invenra Inc, an innovative biotechnology company with proprietary technologies for discovering novel therapeutics, today announced that they have entered into...

Category: Drug Discovery, Other, Pharmaceutical
Posted: January 30, 2025

Orion
Orion Corporation Orionintie 1A, FI-02200 Espoo P.O.Box 65, FI-02101 Espoo

Rentschler Biopharma announces strategic realignment of its global business operations

30 January 2025 – Laupheim, Germany – Rentschler Biopharma SE, a leading global contract development and manufacturing organization (CDMO) for biopharmaceuticals, announced today a realignment of its global business operations...

Category: BioManufacturing
Posted: January 30, 2025

Rentschler Biopharma
info@rentschler-biopharma.com
Erwin-Rentschler-Str. 21 88471 Laupheim Germany

BioMed X Institute Launches New Collaboration with Daiichi Sankyo in Cancer Therapy

German research institute BioMed X started a new partnership with Daiichi Sankyo, a Japanese pharmaceutical company, to advance the development of bi- and multi-specific biologics for treating solid tumors 14 January...

Category: Drug Discovery, Other, Pharmaceutical
Posted: January 14, 2025

BioMed X
info@bio.mx
BioMed X GmbH Im Neuenheimer Feld 515 69120 Heidelberg